What is Teprotumumab

Teprotumumab is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor approved for the treatment of thyroid eye disease.

It is given via intravenous infusion every 3 weeks for a total of 8 doses.

Teprotumumab may cause infusion-related reactions, hyperglycemia, and exacerbation of inflammatory bowel disease.

In utero exposure to teprotumumab may cause fetal harm; therefore, use of the drug during pregnancy should be avoided. Instruct women of child-bearing potential to use effective contraception prior to, during, and for 6 months after treatment with teprotumumab.

Brand Name



  • Graves’ ophthalmopathy
  • thyroid eye disease

For the treatment of thyroid eye disease (i.e., Graves’ ophthalmopathy or thyroid-associated ophthalmopathy)

Side Effects

  1. alopecia
  2. asthenia
  3. diarrhea
  4. dysgeusia
  5. dyspnea
  6. fatigue
  7. headache
  8. hearing loss
  9. hyperacusis
  10. hyperglycemia
  11. hypertension
  12. inflammatory bowel disease
  13. infusion-related reactions
  14. musculoskeletal pain
  15. nausea
  16. sinus tachycardia
  17. xerosis

Monitoring Parameters

  • blood glucose
  • pregnancy testing


  • breast-feeding
  • contraception requirements
  • diabetes mellitus
  • hyperglycemia
  • inflammatory bowel disease
  • infusion-related reactions
  • pregnancy
  • reproductive risk


There are no drug interactions associated with Teprotumumab products.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top